Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

ClinicalTrials.gov ID: NCT00095381

Public ClinicalTrials.gov record NCT00095381. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use

Study identification

NCT ID
NCT00095381
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
BioCryst Pharmaceuticals
Industry
Enrollment
20 participants

Conditions and interventions

Interventions

  • forodesine hydrochloride (BCX-1777) Drug

Drug

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2004
Primary completion
Feb 28, 2007
Completion
Nov 30, 2007
Last update posted
Jan 18, 2012

2004 – 2007

United States locations

U.S. sites
23
U.S. states
15
U.S. cities
21
Facility City State ZIP Site status
Not listed Los Angeles California 90024
Not listed Palo Alto California 94304
Not listed Denver Colorado 80262
Not listed Gainesville Florida 32611
Not listed Lecanto Florida 34461
Not listed Atlanta Georgia 30322
Not listed Chicago Illinois 60611
Not listed Chicago Illinois 60637
Not listed Kansas City Kansas 66160
Not listed New Orleans Louisiana 70118
Not listed Detroit Michigan 48202
Not listed Rolla Missouri 65401
Not listed St Louis Missouri 63110
Not listed Omaha Nebraska 68198
Not listed Hackensack New Jersey 07601
Weil Medical College of Cornell University New York New York 10021
Not listed New York New York 10021
Not listed Syracuse New York 13210
Not listed The Bronx New York 10467
Not listed Spartanburg South Carolina 29303
Not listed Austin Texas 78701
Not listed Houston Texas 77030
Not listed Abingdon Virginia 24211

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00095381, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 18, 2012 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00095381 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →